An essential dose of cisplatin for super-selective intra-arterial infusion concomitant with radiotherapy in patient with maxillary squamous cell carcinoma

Yuji Kanazawa, Hideo Shojaku*, Hiromasa Takakura, Michiro Fujisaka, Hirohiko Tachino, Yukio Watanabe, Gakuto Tomizawa, Hideto Kawabe, Hiroko Shojaku*, Hikaru Seto, Kyoko Otani, Jyunya Fukuoka

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The present study investigated the efficacy and safety of using a lower dose of cisplatin (CDDP) in superselective intra-arterial concurrent chemoradiotherapy (SSIACRT) to treat maxillary squamous cell carcinoma. 10 patients with maxillary squamous cell carcinoma (T3 n = 6, T4a n = 4) without regional or distant metastasis were treated by SSIACRT. The CDDP dose per course was 100 mg/body, i.e. 50-80 mg/m2. 6-9 weeks after SSIACRT, partial maxillectomy was performed on all patients. Clinical and histological responses, survival rates, and adverse events were investigated. 10 (100%) of 10 patients achieved both clinical and pathological complete or partial remission. The 3-year overall and disease-free survival rates were 100 and 90%, respectively. Grade 3 toxicity was experienced by two patients. In conclusion, the SSIACRT regimen with a lower dose of CDDP (100 mg/ body) had an equivalent therapeutic outcome and lower toxic outcome compared to a higher dose of CDDP. This regimen could be an effective and safe therapeutic modality for maxillary squamous cell carcinoma except T4b and N1/2 disease.

Original languageEnglish
Pages (from-to)1985-1991
Number of pages7
JournalEuropean Archives of Oto-Rhino-Laryngology
Volume269
Issue number8
DOIs
StatePublished - 2012/08

Keywords

  • Cisplatin
  • Concurrent chemoradiotherapy
  • Dose
  • Maxillary squamous cell carcinoma
  • Super-selective intra-arterial administration

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint

Dive into the research topics of 'An essential dose of cisplatin for super-selective intra-arterial infusion concomitant with radiotherapy in patient with maxillary squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this